Chinese guideline for lipid management (2023): a new guideline rich in domestic elements for controlling dyslipidemia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. A landscape of metabolic burden and its cardiovascular impact across the adult lifespan: a prospective cohort study of 7.5 million people in Northwestern China.The Lancet regional health. Western Pacific · 2026
   Article
2. Dissociation between subjective sleep quality and lipid dysregulation in underground miners: night shift work as an independent risk factor for hypercholesterolemia.Frontiers in public health · 2026
   Article
3. Research advances in current drugs targeting hyperlipidemia (Review).Molecular medicine reports · 2025
   Review
4. Comparative analysis of three BMI cutoffs for five metabolic abnormalities in the population of Western Guangdong, China.Frontiers in nutrition · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.